/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

BARINTHUS BIOTHERAPEUTICS PLC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.74 0.0337(3.37%) BRNS at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 0.74505
Highest Today 0.7929
Today’s Open 0.76
Prev. Close 0.7159
52 Week High 2.91
52 Week Low 0.64
Day’s Range: Low 0.74505 High 0.7929
52-Week Range: Low 0.64 High 2.91
1 day return -
1 Week return -9.47
1 month return -36.31
3 month return -43.72
6 month return -30.85
1 year return -31.5
3 year return -68.15
5 year return -
10 year return -

Institutional Holdings

M&G PLC 12.88

Alphabet Inc 3.75

SC China Holding Ltd 3.52

M&G (ACS) Japan Equity GBPZ1A 2.70

DC Funds, LP 1.59

Baird Financial Group, Inc. 0.48

The Johns Hopkins University 0.30

Galileo - Biotech Innovation Fund S USD 0.27

HighTower Advisors, LLC 0.09

Renaissance Technologies Corp 0.09

Citadel Advisors Llc 0.04

Janney Montgomery Scott LLC 0.04

Fidelity Nasdaq Composite Index 0.03

Geode Capital Management, LLC 0.03

Morgan Stanley - Brokerage Accounts 0.01

Royal Bank of Canada 0.00

New England Capital Financial Advisors LLC 0.00

Ipswich Inv Mgmt Co Inc 0.00

Millennium Management LLC 0.00

Rhumbline Advisers 0.00

Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 29.23 M

PB Ratio 0.3819

PE Ratio 0.0

Enterprise Value -30.45 M

Total Assets 160.33 M

Volume 24932

Company Financials

Annual Revenue FY23:7259000 7.3M, FY22:44703000 44.7M, FY21:268000 0.3M, FY20:4820257 4.8M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-77243000 -77.2M, FY22:5342000 5.3M, FY21:-50865000 -50.9M, FY20:-17706065 -17.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:14969000 15.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-2024681 -2.0M, Q1/2025:-2041809 -2.0M, Q3/2024:14969000 15.0M, Q2/2024:-1468644 -1.5M

Quarterly Net worth Q3/2025:-14566000 -14.6M, Q2/2025:-21124000 -21.1M, Q1/2025:-19648000 -19.6M, Q3/2024:-8114000 -8.1M, Q2/2024:-16949980 -16.9M

Fund house & investment objective

Company Information Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Organisation Biotechnology

Employees 105

Industry Biotechnology

CEO Mr. William J. Enright MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow